On 17 December 2010, orphan designation (EU/3/10/823) was granted by the European Commission to Dimensione Ricerca S.r.l., Italy, for lomitapide for the treatment of familial chylomicronaemia.

The sponsorship was transferred to Aegerion Pharmaceuticals, France, in February 2012 and subsequently to Aegerion Pharmaceuticals Limited, United Kingdom, in February 2015.

For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.

Key facts

Active substance
Disease / condition
Treatment of familial chylomicronaemia
Date of decision
Orphan decision number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Aegerion Pharmaceuticals Limited
Lakeside House
1 Furzeground Way
Stockley Park East
Uxbridge UB11 1BD
United Kingdom
Tel. +44 (0)20 8622 4100
Fax +44 (0)1748 828 801

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating